In short
Dacomitinib is an oral medication being studied in clinical trials for various types of cancer, particularly non-small cell lung cancer (NSCLC). As a pan-HER inhibitor, it targets multiple proteins involved in cancer growth. This article summarizes key findings from clinical trials investigating dacomitinib's safety, efficacy, and pharmacokinetics in different patient populations.
At a glance
- Main Indications
- Non-small cell lung cancer (NSCLC), particularly with EGFR mutations
- Other Studied Cancers
- Penile squamous cell carcinoma, recurrent glioblastoma
- Administration
- Oral, typically 30-45 mg daily
- Key Efficacy Measures
- Progression-free survival, overall response rate, overall survival
- Common Side Effects
- Skin reactions, diarrhea, fatigue
- Special Populations Studied
- Patients with hepatic impairment, specific EGFR mutations (e.g., T790M)
- Combination Studies
- Dacomitinib plus anlotinib for advanced NSCLC
- Pharmacokinetic Assessments
- Studies in healthy volunteers and those with hepatic impairment
What is Dacomitinib?
Dacomitinib is a medication used in the treatment of certain types of cancer. It is also known by other names such as PF-00299804, VIZIMPRO, and DACOPLICE. Dacomitinib belongs to a class of drugs called kinase inhibitors, which work by blocking specific proteins that contribute to cancer growth.
How Dacomitinib Works
Dacomitinib is what's known as a pan-HER inhibitor. This means it targets and blocks multiple proteins in the HER (Human Epidermal Growth Factor Receptor) family, including EGFR (Epidermal Growth Factor Receptor). These proteins are often overactive in cancer cells, causing them to grow and divide uncontrollably. By inhibiting these proteins, dacomitinib can help slow down or stop the growth of cancer cells.
Conditions Treated with Dacomitinib
Dacomitinib is primarily used to treat certain types of non-small cell lung cancer (NSCLC). Specifically, it is indicated for:
- First-line treatment of metastatic NSCLC with specific EGFR gene mutations (exon 19 deletion or exon 21 L858R substitution mutations). Metastatic means the cancer has spread to other parts of the body.
- Advanced NSCLC in patients who have previously been treated with chemotherapy or other targeted therapies.
In addition to lung cancer, dacomitinib has also been studied for use in other types of cancer, such as:
- Advanced or metastatic squamous cell carcinoma of the penis. This is a rare type of cancer that affects the skin and tissues of the penis.
How Dacomitinib is Administered
Dacomitinib is taken orally in the form of tablets. The typical dosage is:
- 45 mg taken once daily
- It should be taken at approximately the same time each day
- Treatment continues until the disease progresses or unacceptable side effects occur
In some cases, the dosage may be adjusted based on individual patient factors or side effects. For example, some studies have explored different dosing schedules, such as intermittent dosing (taking the medication for a few days, then having a break) to manage side effects.
Effectiveness of Dacomitinib
Clinical trials have shown that dacomitinib can be effective in treating certain types of NSCLC. In a large study comparing dacomitinib to another drug called gefitinib:
- Patients taking dacomitinib had a longer progression-free survival (the time during which the cancer did not worsen) compared to those taking gefitinib.
- Some patients experienced a significant reduction in tumor size (called an objective response) with dacomitinib treatment.
It's important to note that the effectiveness can vary from person to person, and your doctor will consider various factors when deciding if dacomitinib is the right treatment for you.
Side Effects and Safety
Like all medications, dacomitinib can cause side effects. Some of the most common side effects include:
- Skin-related issues: Such as rash, dry skin, and nail problems
- Diarrhea
- Mouth sores
- Decreased appetite
- Fatigue
In some cases, these side effects can be severe. Your healthcare team will monitor you closely and may adjust your treatment if needed. They may also prescribe additional medications to help manage side effects.
Special Considerations
There are some important things to consider when taking dacomitinib:
- Liver function: Dacomitinib is processed by the liver, so people with liver problems may need special monitoring or dosage adjustments.
- Pregnancy and breastfeeding: Dacomitinib can harm an unborn baby, so it should not be used during pregnancy. It's also not known if it passes into breast milk, so breastfeeding is not recommended while taking this medication.
- Drug interactions: Dacomitinib can interact with other medications, so it's important to tell your doctor about all drugs and supplements you're taking.
- Monitoring: Regular check-ups and tests will be needed to monitor your response to the treatment and check for side effects.
Remember, this information is general, and your experience with dacomitinib may be different. Always consult with your healthcare provider for personalized advice and information about your treatment.